Key statistics
On Thursday, Resmed Inc (RMD:MEX) closed at 3,836.00, -1.64% below its 52-week high of 3,900.00, set on Jun 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3,836.00 |
---|---|
High | 3,836.00 |
Low | 3,836.00 |
Bid | -- |
Offer | -- |
Previous close | 3,836.00 |
Average volume | -- |
---|---|
Shares outstanding | 146.93m |
Free float | 145.76m |
P/E (TTM) | 36.25 |
Market cap | 36.86bn USD |
EPS (TTM) | 6.92 USD |
Annual div (ADY) | 39.52 MXN |
---|---|
Annual div yield (ADY) | 1.03% |
Div ex-date | Aug 15 2024 |
Div pay-date | Sep 19 2024 |
Data delayed at least 20 minutes, as of Jul 25 2024 12:30 BST.
More ▼
Announcements
- ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange
- Vaping Expected to Increase COPD Health and Economic Burden by 2050
- ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
- ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
- ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
- ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
- PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
- Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
- ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
- ResMed Announces Participation in the RBCCM Global Healthcare Conference
More ▼